Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKRO NASDAQ:APLS NYSE:HHH NASDAQ:TSHA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKROAkero Therapeutics$44.04-1.3%$49.30$21.34▼$58.40$3.52B-0.241.36 million shs45,268 shsAPLSApellis Pharmaceuticals$26.37-1.8%$23.33$16.10▼$39.51$3.34B0.732.28 million shs110,315 shsHHHHoward Hughes$78.89+1.0%$71.99$61.40▼$87.77$4.69B1.21456,942 shs42,539 shsTSHATaysha Gene Therapies$3.25-1.1%$2.77$1.05▼$3.40$885.22M0.982.94 million shs210,393 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKROAkero Therapeutics+0.11%-1.80%-11.57%-15.75%+69.66%APLSApellis Pharmaceuticals-0.26%-4.72%+10.14%+39.28%-32.80%HHHHoward Hughes-1.05%+4.49%+9.79%+11.28%+8.09%TSHATaysha Gene Therapies+1.23%+15.49%+20.59%+22.85%+43.23%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKROAkero Therapeutics$44.04-1.3%$49.30$21.34▼$58.40$3.52B-0.241.36 million shs45,268 shsAPLSApellis Pharmaceuticals$26.37-1.8%$23.33$16.10▼$39.51$3.34B0.732.28 million shs110,315 shsHHHHoward Hughes$78.89+1.0%$71.99$61.40▼$87.77$4.69B1.21456,942 shs42,539 shsTSHATaysha Gene Therapies$3.25-1.1%$2.77$1.05▼$3.40$885.22M0.982.94 million shs210,393 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKROAkero Therapeutics+0.11%-1.80%-11.57%-15.75%+69.66%APLSApellis Pharmaceuticals-0.26%-4.72%+10.14%+39.28%-32.80%HHHHoward Hughes-1.05%+4.49%+9.79%+11.28%+8.09%TSHATaysha Gene Therapies+1.23%+15.49%+20.59%+22.85%+43.23%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKROAkero Therapeutics 3.00Buy$81.1481.85% UpsideAPLSApellis Pharmaceuticals 2.58Moderate Buy$34.1227.11% UpsideHHHHoward Hughes 2.50Moderate Buy$83.336.66% UpsideTSHATaysha Gene Therapies 3.00Buy$8.29152.61% UpsideCurrent Analyst Ratings BreakdownLatest TSHA, HHH, AKRO, and APLS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/4/2025AKROAkero TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$72.008/29/2025HHHHoward HughesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$76.00 ➝ $85.008/22/2025HHHHoward HughesZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/13/2025TSHATaysha Gene TherapiesWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$7.50 ➝ $8.008/12/2025TSHATaysha Gene TherapiesChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$9.00 ➝ $10.008/4/2025AKROAkero TherapeuticsCowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy8/4/2025AKROAkero TherapeuticsTD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$76.008/4/2025APLSApellis PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$35.00 ➝ $37.008/1/2025APLSApellis PharmaceuticalsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSector Perform$17.00 ➝ $19.008/1/2025APLSApellis PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$39.00 ➝ $40.008/1/2025APLSApellis PharmaceuticalsRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$52.00 ➝ $50.00(Data available from 9/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKROAkero TherapeuticsN/AN/AN/AN/A$10.75 per shareN/AAPLSApellis Pharmaceuticals$754.65M4.49N/AN/A$1.84 per share14.59HHHHoward Hughes$1.75B2.65$9.59 per share8.15$56.65 per share1.38TSHATaysha Gene Therapies$8.10M110.49N/AN/A$0.35 per share9.37Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKROAkero Therapeutics-$252.06M-$2.00N/AN/AN/AN/A-15.84%-14.59%11/14/2025 (Estimated)APLSApellis Pharmaceuticals-$197.88M-$1.82N/AN/AN/A-30.24%-116.09%-26.72%11/4/2025 (Estimated)HHHHoward Hughes$200.55M$4.5717.1084.92N/A12.85%10.51%3.15%N/ATSHATaysha Gene Therapies-$89.30M-$0.34N/AN/AN/A-1,144.97%-78.44%-44.82%11/12/2025 (Estimated)Latest TSHA, HHH, AKRO, and APLS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025TSHATaysha Gene Therapies-$0.07-$0.09-$0.02-$0.09$1.61 million$1.99 million8/8/2025Q2 2025AKROAkero Therapeutics-$0.97-$0.86+$0.11-$0.86N/AN/A7/31/2025Q2 2025APLSApellis Pharmaceuticals-$0.44-$0.33+$0.11-$0.33$187.91 million$171.39 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKROAkero TherapeuticsN/AN/AN/AN/AN/AAPLSApellis PharmaceuticalsN/AN/AN/AN/AN/AHHHHoward HughesN/AN/AN/AN/AN/ATSHATaysha Gene TherapiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKROAkero Therapeutics0.0212.6612.66APLSApellis Pharmaceuticals2.903.773.16HHHHoward Hughes1.851.181.18TSHATaysha Gene Therapies0.1712.4812.48Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKROAkero TherapeuticsN/AAPLSApellis Pharmaceuticals96.29%HHHHoward Hughes93.83%TSHATaysha Gene Therapies77.70%Insider OwnershipCompanyInsider OwnershipAKROAkero Therapeutics7.07%APLSApellis Pharmaceuticals6.80%HHHHoward Hughes48.00%TSHATaysha Gene Therapies3.78%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKROAkero Therapeutics3079.99 million74.33 millionOptionableAPLSApellis Pharmaceuticals770126.29 million117.70 millionOptionableHHHHoward Hughes60859.40 million30.89 millionOptionableTSHATaysha Gene Therapies180272.80 million262.48 millionOptionableTSHA, HHH, AKRO, and APLS HeadlinesRecent News About These CompaniesTaysha Gene Therapies (NASDAQ:TSHA) Sets New 52-Week High - Here's WhySeptember 7 at 2:45 AM | americanbankingnews.comTaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)September 5, 2025 | globenewswire.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives $8.29 Consensus PT from AnalystsSeptember 5, 2025 | americanbankingnews.comTaysha Gene Therapies, Inc. $TSHA Stake Increased by ADAR1 Capital Management LLCSeptember 4, 2025 | marketbeat.comPalo Alto Investors LP Purchases 608,200 Shares of Taysha Gene Therapies, Inc. $TSHASeptember 4, 2025 | marketbeat.comNuveen LLC Acquires New Stake in Taysha Gene Therapies, Inc. $TSHASeptember 4, 2025 | marketbeat.comTaysha Gene Therapies, Inc.September 3, 2025 | edition.cnn.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Consensus Rating of "Buy" from BrokeragesSeptember 3, 2025 | marketbeat.comPiper Sandler Maintains a Buy on Taysha Gene Therapies (TSHA), Sets a PT of $9August 25, 2025 | msn.comKovitz Investment Group Partners LLC Invests $407,000 in Taysha Gene Therapies, Inc. $TSHAAugust 24, 2025 | marketbeat.comFY2025 Earnings Forecast for TSHA Issued By Chardan CapitalAugust 19, 2025 | marketbeat.comCantor Fitzgerald Issues Negative Forecast for TSHA EarningsAugust 17, 2025 | marketbeat.comTaysha Gene Therapies (NASDAQ:TSHA) Shares Gap Up on Analyst UpgradeAugust 15, 2025 | marketbeat.comWells Fargo & Company Increases Taysha Gene Therapies (NASDAQ:TSHA) Price Target to $8.00August 15, 2025 | marketbeat.comTaysha Gene Therapies (NASDAQ:TSHA) Price Target Raised to $10.00August 14, 2025 | marketbeat.comTaysha Gene Therapies price target raised to $14 from $11 at CanaccordAugust 13, 2025 | msn.com4TSHA : A Glimpse Into The Expert Outlook On Taysha Gene Therapies Through...August 13, 2025 | benzinga.comTaysha Gene Therapies (NASDAQ:TSHA) Issues Earnings ResultsAugust 13, 2025 | marketbeat.comTaysha Gene Therapies Inc (TSHA) Q2 2025 Earnings Call Highlights: Regulatory Milestones and ...August 13, 2025 | finance.yahoo.comXTX Topco Ltd Takes $282,000 Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)August 13, 2025 | marketbeat.comTaysha Gene Therapies price target raised to $10 from $9 at ChardanAugust 13, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTSHA, HHH, AKRO, and APLS Company DescriptionsAkero Therapeutics NASDAQ:AKRO$44.04 -0.58 (-1.30%) As of 10:25 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.Apellis Pharmaceuticals NASDAQ:APLS$26.36 -0.48 (-1.77%) As of 10:25 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.Howard Hughes NYSE:HHH$78.89 +0.77 (+0.99%) As of 10:25 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Howard Hughes Holdings Inc., together with its subsidiaries, operates as a real estate development company in the United States. It operates in four segments: Operating Assets; Master Planned Communities (MPCs); Seaport; and Strategic Developments. The Operating Assets segment consists of developed or acquired retail, office, and multi-family properties along with other retail investments. Its MPCs segment develops, sells, and leases residential and commercial land designated for long-term community development projects in and around Las Vegas, Nevada; Houston, Texas; and Phoenix, Arizona. The Seaport segment is involved in the landlord operations, managed businesses, and events and sponsorships services of its restaurant, retail, and entertain properties in Pier 17, New York City; Historic Area/Uplands; and Tin Building, as well as in 250 Water Street and in the Jean-Georges restaurants. The Strategic Development segment develops and redevelops residential condominiums and commercial properties. It serves homebuilders. Howard Hughes Holdings Inc. was founded in 2010 and is headquartered in The Woodlands, Texas.Taysha Gene Therapies NASDAQ:TSHA$3.24 -0.04 (-1.07%) As of 10:25 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle Has Spoken: AI Changes Everything Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Should You Buy Figma Stock After Its 55% Post-IPO Drop? Ulta Beauty Stock: Strong Growth, Short-Term Volatility Ahead Joby's Stock Is Quiet, But a Storm of Catalysts Is Brewing Beyond DIY: Home Depot's Conquest of the Professional Market The Quiet Before the Catalyst: Vertical Aerospace's Next Move Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
